We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$357M
AUM Growth
+$14.3M
Cap. Flow
-$377K
Cap. Flow %
-0.11%
Top 10 Hldgs %
60.48%
Holding
73
New
21
Increased
19
Reduced
16
Closed
11

Top Buys

Rank Stock Value
1
ENSG icon
The Ensign Group
ENSG
+$7.79M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.69M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$6.13M
4
ILMN icon
Illumina
ILMN
+$5.94M
5
CNC icon
Centene
CNC
+$4.1M

Top Sells

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$14.1M
2
AMRN
Amarin Corp
AMRN
+$9.2M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.15M
4
ABMD
Abiomed Inc
ABMD
+$7.81M
5
AERI
Aerie Pharmaceuticals
AERI
+$5.45M

Sector Composition

Rank Sector Weight
1 Healthcare 82.49%
2 Industrials 9.51%
3 Financials 4.31%
4 Miscellaneous 1.99%
5 Real Estate 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
26
MacroGenics
MGNX
$263M
$3.23M 0.91%
+190,623
New +$3.27M
HSKA
27
DELISTED
Heska Corp
HSKA
$2.97M 0.83%
34,924
+28,244
+423% +$2.2M
APLS
28
DELISTED
Apellis Pharmaceuticals
APLS
$2.97M 0.83%
117,309
+12,960
+12% +$264K
MYOK
29
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$2.84M 0.8%
56,652
+21,600
+62% +$1.05M
ELV icon
30
Elevance Health
ELV
$85.5B
$2.82M 0.79%
+10,000
New +$2.73M
HUM icon
31
Humana
HUM
$46.3B
$2.66M 0.74%
+10,000
New +$2.54M
SRPT icon
32
Sarepta Therapeutics
SRPT
$2.2B
$2.52M 0.7%
16,554
-67,020
-80% -$8.15M
GHDX
33
DELISTED
Genomic Health, Inc.
GHDX
$2.23M 0.63%
+38,403
New +$2.27M
XENE icon
34
Xenon Pharmaceuticals
XENE
$5.81B
$2.21M 0.62%
224,340
– –
PTCT icon
35
PTC Therapeutics
PTCT
$5.85B
$2.19M 0.61%
48,600
-52,000
-52% -$2.05M
MDCO
36
DELISTED
Medicines Co
MDCO
$2.09M 0.58%
57,200
-19,000
-25% -$620K
COLL icon
37
Collegium Pharmaceutical
COLL
$786M
$1.85M 0.52%
+141,000
New +$1.89M
ZGNX
38
PUT
DELISTED
Zogenix, Inc.
ZGNX
$1.74M 0.49%
+36,400
New +$1.47M
BDSI
39
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.66M 0.46%
+356,274
New +$1.66M
TLGT
40
DELISTED
Teligent, Inc
TLGT
$1.63M 0.46%
258,488
+1,000
+0.4% +$8.15K
SBRA icon
41
Sabra Healthcare REIT
SBRA
$5.27B
$1.55M 0.43%
+78,600
New +$1.53M
OHI icon
42
Omega Healthcare
OHI
$13.9B
$1.52M 0.43%
+41,400
New +$1.51M
LTC
43
LTC Properties
LTC
$2.19B
$1.51M 0.42%
+33,027
New +$1.5M
CTRE icon
44
CareTrust REIT
CTRE
$9.22B
$1.5M 0.42%
62,464
+21,200
+51% +$514K
BCRX icon
45
BioCryst Pharmaceuticals
BCRX
$2.51B
$1.3M 0.36%
342,460
-70,416
-17% -$424K
IVC
46
DELISTED
Invacare Corporation
IVC
$1.09M 0.31%
210,283
+131,202
+166% +$855K
AFMD
47
DELISTED
Affimed
AFMD
$925K 0.26%
32,217
– –
PRVB
48
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$891K 0.25%
+73,661
New +$401K
OPTN
49
DELISTED
OptiNose
OPTN
$744K 0.21%
+7,007
New +$923K
EIGR
50
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$739K 0.21%
2,324
– –
1
2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2019 Portfolio in Review

As of Q2 2019, Eversept Partners held 73 positions worth $357M, up 4.2% from $343M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners's Q2 2019 filing shows 21 new, 19 increased, 16 reduced and 11 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 87,140 shares worth $6.32M. The largest sale was NuVasive, Inc., an estimated $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Industrials and Financials.

  • Eversept Partners's largest Q2 2019 buy was Alnylam Pharmaceuticals: 87,140 shares worth $6.32M.
  • Eversept Partners added most to The Ensign Group in Q2 2019, an estimated $7.79M increase.
  • Eversept Partners's biggest Q2 2019 reduction was NuVasive, Inc., cutting an estimated $14.1M.
  • Eversept Partners fully exited Abiomed Inc in Q2 2019, selling an estimated $7.81M.
  • Eversept Partners's ten largest holdings make up 60% of its $357M portfolio in Q2 2019.
  • Eversept Partners opened 21 new positions and closed 11 in Q2 2019.
  • Eversept Partners's portfolio value rose 4.2% quarter-over-quarter to $357M.

Based on Eversept Partners's 13F filing for Q2 2019, filed 13 Aug 2019.